| _version_ |
1860797346649997312
|
| building |
INTELEK Repository
|
| caption |
BMC Proc, doi:10.1186/s12919-019-0169-6
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| copyright |
The Author(s).
|
| date |
2019-11-24 10:02:17
|
| format |
Restricted Document
|
| id |
12346
|
| institution |
UniSZA
|
| originalfilename |
6646-01-FH02-FSK-19-36223.pdf
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12346
|
| spelling |
12346 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=12346 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf 1.6 Adobe Acrobat Pro DC 20 Paper Capture Plug-in 23 The Author(s). 2019-11-24 10:02:17 BMC Proc, doi:10.1186/s12919-019-0169-6 BMC Proc doi:10.1186/s12919-019-0169-6 6646-01-FH02-FSK-19-36223.pdf UniSZA Private Access Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B BMC Proceedings Background Tuberculosis (TB) remains a major worldwide health problem which causes more than 1.3 million deaths annually. The development of a new vaccine as a replacement of Bacille Calmette Guerin (BCG) or to improve its efficacy is one of the goals mooted by the World Health Organization (WHO) to control TB. Mycobacterium smegmatis (M. smegmatis) is nonpathogenic and commensal in humans, which shares many characteristics with Mycobacterium tuberculosis (M. tuberculosis). Mycobacterial vectors including M. smegmatis have been successfully used in the development of experimental vaccines against TB. 13 8 21-22
|
| spellingShingle |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| subject |
BMC Proc
doi:10.1186/s12919-019-0169-6
|
| summary |
Background Tuberculosis (TB) remains a major worldwide health problem which causes more than 1.3 million deaths annually. The development of a new vaccine as a replacement of Bacille Calmette Guerin (BCG) or to improve its efficacy is one of the goals mooted by the World Health Organization (WHO) to control TB. Mycobacterium smegmatis (M. smegmatis) is nonpathogenic and commensal in humans, which shares many characteristics with Mycobacterium tuberculosis (M. tuberculosis). Mycobacterial vectors including M. smegmatis have been successfully used in the development of experimental vaccines against TB.
|
| title |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| title_full |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| title_fullStr |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| title_full_unstemmed |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| title_short |
Modulation of macrophage activation marker induced by recombinant Mycobacterium smegmatis expressing Antigen-85B
|
| title_sort |
modulation of macrophage activation marker induced by recombinant mycobacterium smegmatis expressing antigen-85b
|